NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
Clinical Trials
29 trialsNCT04586244 2025-10-30
Optimus
Incyte Corporation
Phase 2 Terminated
NCT04887831 2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04936230 2025-08-17
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04294277 2025-04-18
PEGASUS
European Association of Urology Research Foundation
Phase 2 Terminated
NCT04322643 2025-02-25
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT03272217 2025-01-07
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03486197 2024-11-20
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Phase 2 Terminated
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03737123 2023-09-13
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03606174 2023-08-24
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Phase 2 Terminated
NCT04039867 2023-08-21
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
University of California, Irvine
Phase 2 Terminated
NCT03397394 2023-06-09
ATLAS
pharmaand GmbH
Phase 2 Terminated
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT01093066 2021-12-30
ReChiVe
Centre Hospitalier Universitaire de Saint Etienne
Phase 2 Terminated
NCT03287050 2021-12-15
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT03115801 2021-09-22
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
Phase 2 Terminated
NCT04066595 2021-08-30
CabUC
Johannes Gutenberg University Mainz
Phase 2 Terminated
NCT04579133 2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Phase 2 Terminated
NCT02693717 2021-05-20
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03029832 2019-05-31
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Genentech, Inc.
Phase 2 Terminated
NCT01856101 2019-04-10
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT02334527 2018-11-16
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01042795 2017-06-28
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase 2 Terminated
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT02479178 2016-04-14
iNSITE2
BIND Therapeutics
Phase 2 Terminated
NCT00479089 2015-11-02
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00127595 2005-08-24
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated